There are four different types of PPTA membership: Global, Regional, Source, and Associate.
Global membership is available to businesses or groups of businesses engaged in the manufacture of plasma protein therapies that meet the following criteria:
Regional membership (i.e., Europe, North America) is available and limited to businesses or groups of businesses engaged in the manufacture of products in two or fewer continents that meet each of the following criteria:
Source Membership is available to organizations engaged in the collecting, manufacturing, processing or distributing of plasma for further manufacture and that adhere to the highest standards of conduct as described in the Code of Ethics.
Associate Membership is available to organizations or groups of organizations providing services to businesses or organizations that qualify for either Global, Regional or Source membership in the Association. Associate members shall not be eligible to vote on Association matters or to hold office as directors or officers of the Association.
For information on how to become a member of PPTA, contact the Membership Services office of PPTA, by calling 202-789-3100 or by emailing firstname.lastname@example.org.
PPTA welcomes positive developments but regrets missed opportunities to support plasma donors and patients who rely on plasma-derived medicinal products (PDMPs)
Brussels, Belgium (July 14, 2022). While the text of the draft regulation on Substances of Human Origin (SoHo) addresses a number of PPTA’s concerns, it has missed the opportunity to help Member States increase plasma collection to improve the reliable availability of life-saving, plasma-derived therapies to patients with a wide range of rare and complex, chronic diseases. As much as 38% of the plasma used to produce medicines for the EU’s 300,000 rare disease patients who rely on PDMPs comes from the U.S., a reliance highlighted during the pandemic, when critical plasma donations declined significantly.Read More
PPTA considers that the current MPXV outbreak is not a concern for the safety margins of plasma protein therapies manufactured by PPTA member companies. This assessment is also shared by other concerned parties (AABB, WHO).
Since May 2022, Monkeypox virus (MPXV) infections have been reported in non-endemic countries across Europe and North America (WHO, CDC, ECDC). People who use plasma protein therapies are understandably concerned about whether their therapies remain safe, with respect to MPXV. To address this issue, PPTA has summarized currently available facts.Read More
It is with great pleasure that the Plasma Protein Therapeutics Association (PPTA) announces the election of Giles Platford from Takeda to the Chair of the PPTA Global Board.Read More
The need for plasma and plasma donors is more urgent than ever before. Visit givingplasma.org to learn more and to find a donation center near you.